【摘要】：目的:觀察參芪補(bǔ)肺方對慢阻肺穩(wěn)定期(肺腎氣虛兼血瘀證)患者的6min步行距離、癥狀積分、急性加重次數(shù)、血清IL-17水平的影響,評(píng)價(jià)其臨床療效及安全性。方法:共選取符合納入標(biāo)準(zhǔn)的COPD穩(wěn)定期患者64例,治療組、對照組各32例,治療組:給予噻托溴銨粉吸入劑每次1吸,每吸(18 μg),日1次,加服參芪補(bǔ)肺方,每日一劑,早晚飯后各服150ml,溫水送服;對照組:給予噻托溴銨粉吸入劑每次1吸,每吸(18μg),日1次,加服補(bǔ)肺活血膠囊,每次4粒,每日3次口服。2組療程均為90天。在治療前后統(tǒng)計(jì)兩組患者進(jìn)行6min步行距離、血清IL-17水平、中醫(yī)主證證候積分,統(tǒng)計(jì)兩組治療后6個(gè)月急性加重次數(shù)。結(jié)果:1.兩組患者治療后6min步行距離均上升(P0.05),但組間比較無差異(P0.05)。2.治療后6個(gè)月治療組急性加重次數(shù)明顯少于對照組,組間比較有統(tǒng)計(jì)學(xué)意義(P0.05)。3.兩組患者治療后血清IL-17水平較治療前均降低(P0.05);兩組患者治療后血清IL-17水平比較(P0.05),組間比較有統(tǒng)計(jì)學(xué)意義,治療組降低血清IL-17水平優(yōu)于對照組。4.兩組患者治療后中醫(yī)主證證候總分均降低(P0.05),且治療組優(yōu)于對照組(P0.05)。5.兩組患者中醫(yī)主證證候療效無統(tǒng)計(jì)學(xué)意義,療效相當(dāng)(P0.05)。6.兩組患者治療前后安全性指標(biāo)檢測均無臨床意義。結(jié)論:1.參芪補(bǔ)肺方能改善患者中醫(yī)主證證候、降低急性加重次數(shù)、提高6min步行距離。2.參芪補(bǔ)肺方能夠降低血清中IL-17的水平。3.參芪補(bǔ)肺方安全有效,適宜在臨床中推廣應(yīng)用。
[Abstract]:Objective: to observe the effect of Shenqi Bufei recipe on 6min walking distance, symptom score, acute exacerbation times and serum IL-17 level in patients with chronic obstructive lung at stable stage (lung and kidney qi deficiency and blood stasis syndrome), and to evaluate its clinical efficacy and safety. Methods: a total of 64 patients with stable COPD, 32 patients in treatment group and 32 patients in control group, were selected. The treatment group was given tiotropium bromide powder inhalation once a time (18 渭 g), / d), plus Shenqi Bufei recipe once a day. The control group was given tiotropium bromide powder inhaler once a time, every time (18 渭 g), day), plus Bufei Huoxue capsule, 4 capsules each time, 3 times a day. The course of treatment in both groups was 90 days. Before and after treatment, the walking distance of 6min, the level of serum IL-17, the integral of main syndromes of TCM and the times of acute exacerbation after 6 months of treatment were counted. The result is 1: 1. The walking distance of 6min increased in both groups after treatment (P0.05), but there was no difference between the two groups (P0.05). Six months after treatment, the number of acute exacerbations in the treatment group was significantly lower than that in the control group, and there was statistical significance between the two groups (P0.05). After treatment, the serum IL-17 level in the two groups was lower than that before treatment (P0.05), the serum IL-17 level in the two groups after treatment (P0.05), the comparison between the two groups was statistically significant, the treatment group decreased the serum IL-17 level was better than the control group. 4. After treatment, the total scores of main syndromes of TCM decreased in both groups (P0.05), and the treatment group was superior to the control group (P0.05). Two groups of patients with traditional Chinese medicine syndromes syndrome efficacy was not statistically significant, the efficacy was comparable (P0.05). 6. There was no clinical significance for the detection of safety indexes in both groups before and after treatment. Conclusion: 1. Shenqi Bufei prescription can improve the syndrome of TCM, reduce the times of acute aggravation, and improve the walking distance of 6min. 2. Shenqi Bufei prescription can reduce the level of IL-17 in serum. 3. 3. Shenqi Bufei prescription is safe and effective and suitable for clinical application.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R563.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張溪;張忠德;;調(diào)補(bǔ)肺腎法治療特發(fā)性肺間質(zhì)纖維化的臨床研究[J];廣州中醫(yī)藥大學(xué)學(xué)報(bào);2010年06期

2 嚴(yán)紅梅;;三伏天補(bǔ)肺扶正湯治療慢性阻塞性肺疾病穩(wěn)定期療效觀察[J];社區(qū)醫(yī)學(xué)雜志;2011年24期

3 楊君;;注重補(bǔ)肺 祛病延年[J];長壽;2006年12期

4 唯芳;;秋風(fēng)起,補(bǔ)肺氣[J];家庭藥師;2012年11期

5 殷海昌;;老年養(yǎng)生需常補(bǔ)肺[J];家庭醫(yī)學(xué);1992年09期

6 容小興;滋陰補(bǔ)肺藥膳[J];藥膳食療;2003年11期

7 彭銘泉 ,賴得輝;滋陰補(bǔ)肺藥膳[J];藥膳食療;2003年02期

8 賈滿倉;補(bǔ)肺潤腸法治療糖尿病性便秘90例[J];河南中醫(yī);2004年09期

9 翟玉民;;補(bǔ)肺納腎湯治療慢性阻塞性肺氣腫穩(wěn)定期62例[J];光明中醫(yī);2009年03期

10 李仁銘;;補(bǔ)肺潤腸法治療糖尿病性便秘療效觀察[J];湖北中醫(yī)雜志;2010年05期

相關(guān)會(huì)議論文 前4條

1 李榮芝;;老年人冬季宜補(bǔ)肺[A];中國中醫(yī)研究院基礎(chǔ)理論研究所學(xué)術(shù)論文匯編[C];1997年

2 李道五;張志遠(yuǎn);劉申;;補(bǔ)肺潤腸法治療糖尿病性便秘70例療效觀察[A];第六次中國中西醫(yī)結(jié)合糖尿病學(xué)術(shù)會(huì)議論文匯編[C];2002年

3 吳佳莉;;赤紅補(bǔ)肺膠囊對慢性肺源性心臟病患者血流動(dòng)力學(xué)及心功能的影響[A];第十三次全國中西醫(yī)結(jié)合虛證與老年醫(yī)學(xué)學(xué)術(shù)研討會(huì)論文集[C];2013年

4 李建生;崔紅新;田燕歌;李亞;謝洋;;調(diào)補(bǔ)肺腎三法干預(yù)COPD大鼠效果及遠(yuǎn)后效應(yīng)的R值綜合評(píng)價(jià)研究[A];第十一次中國中西醫(yī)結(jié)合實(shí)驗(yàn)醫(yī)學(xué)學(xué)術(shù)研討會(huì)論文匯編[C];2013年

相關(guān)重要報(bào)紙文章 前10條

1 劉劍;注重補(bǔ)肺祛病延年[N];中國醫(yī)藥報(bào);2007年

2 通訊員 劉維雅;滋陰補(bǔ)肺腎 養(yǎng)血潤干燥[N];中國中醫(yī)藥報(bào);2014年

3 韓素芹;人到老年要補(bǔ)肺[N];大眾衛(wèi)生報(bào);2008年

4 琪東;人到老年要“補(bǔ)肺”[N];民族醫(yī)藥報(bào);2006年

5 錢釗;納氣呼吸助補(bǔ)肺[N];醫(yī)藥養(yǎng)生保健報(bào);2007年

6 中國中醫(yī)科學(xué)院西苑醫(yī)院 苗青 許宗偉;補(bǔ)肺腎扶正 祛痰瘀通絡(luò)[N];中國中醫(yī)藥報(bào);2014年

7 劉繼林;補(bǔ)肺氣治療慢性化膿性鼻竇炎[N];農(nóng)村醫(yī)藥報(bào)（漢）;2003年

8 林子原;雙補(bǔ)肺腎用蛤蚧[N];醫(yī)藥養(yǎng)生保健報(bào);2007年

9 成都中醫(yī)藥大學(xué)藥學(xué)院教授 劉繼林;補(bǔ)肺氣治療慢性化膿性鼻竇炎[N];家庭醫(yī)生報(bào);2003年

10 北京中醫(yī)藥大學(xué) 劉蕊潔;補(bǔ)肺脾治發(fā)熱[N];中國中醫(yī)藥報(bào);2011年

相關(guān)博士學(xué)位論文 前3條

1 郅扶e，

本文編號(hào)：2277654